These encouraging observations have helped us to develop a highly specific and potent AR inhibitor, fidarestat, which has been tested in the phase-iii clinical studies for diabetic neuropathy and found to be safe for human use, as a potential antioxidative, anti-inflammatory, antiangiogenic, antimitogenic, and chemopreventive drug for preventing inflammatory diseases such as allergic asthma, colon cancer, and uveitis. This evidence concerns the gene AR and colonic neoplasm.